Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays.

PURPOSE Pancreatic endocrine neoplasms (PENs) are rare, mostly well-differentiated endocrine neoplasms, whose biology has been poorly characterized. Global expression microarrays can document abnormal pathways that impact on tumorigenesis and disease progression. EXPERIMENTAL DESIGN RNA was extracted from eight well-differentiated PENs and three highly enriched pancreatic islet cell samples (80-90% purity), and examined using the Affymetrix U133A oligonucleotide microarray. Microarray data were normalized using dCHIP for identification of differentially expressed genes. PEN tissue microarrays were constructed from 53 archival PENs for immunohistochemical validation of microarray data. RESULTS Sixty-six transcripts were overexpressed > or =3-fold in PENs compared with normal islet cells, including putative oncogenes (MLLT10/AF10), growth factors [insulin-like growth factor-binding protein 3 (IGFBP3)], cell adhesion and migration molecules (fibronectin), and endothelial elements (MUC18/MelCAM and CD31). A total of 119 transcripts were underexpressed < or =3-fold in PENs compared with normal islet cells, including cell cycle checkpoint proteins (p21/Cip1), the MIC2 (CD99) cell surface glycoprotein, putative metastasis suppressor genes (NME3), and junD, a MEN1-regulated transcription factor. Using PEN tissue microarrays, we confirmed the differential up-regulation of IGFBP3 (70%) and fibronectin (22%) and differential down-regulation of p21 (46%) and MIC2 (CD99; 91%) in PENs versus normal pancreatic islets. IGFBP3 overexpression was significantly more common in metastatic (93%) versus primary PEN lesions (60%), P=0.022. Fibronectin overexpression demonstrated a trend toward significance in lymphatic PEN metastases (55%) compared with primary PEN lesions (24%; P=0.14). CONCLUSIONS Global expression analysis provides insight into tumorigenic pathways in PENs and may identify potential prognostic and therapeutic markers for these uncommon neoplasms.

[1]  B. Hoffman,et al.  Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes , 2002, Breast Cancer Research and Treatment.

[2]  F. Sessa,et al.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours , 1996, Virchows Archiv.

[3]  Judith P. Johnson.  Cell Adhesion Molecules in the Development and Progression of Malignant Melanoma , 2004, Cancer and Metastasis Reviews.

[4]  K. Lillemoe,et al.  Identification of novel cellular targets in biliary tract cancers using global gene expression technology. , 2003, The American journal of pathology.

[5]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[6]  C. Paraskeva,et al.  Transcriptional upregulation of the insulin-like growth factor binding protein IGFBP-3 by sodium butyrate increases IGF-independent apoptosis in human colonic adenoma-derived epithelial cells. , 2003, Carcinogenesis.

[7]  S. Beghelli,et al.  Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms , 2002, Journal of surgical oncology.

[8]  R. Hruban,et al.  Primitive Neuroectodermal Tumors of the Pancreas: A Report of Seven Cases of a Rare Neoplasm , 2002, The American journal of surgical pathology.

[9]  R. Schwendener,et al.  Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes , 2002, British Journal of Cancer.

[10]  J. Labat-Robert,et al.  Fibronectin in malignancy. , 2002, Seminars in cancer biology.

[11]  C. Park,et al.  Comparative study of non‐functional islet cell tumors and pancreatic solid and papillary neoplasms: Biological behavior and immunohistochemistry , 2002, Pathology international.

[12]  S. R. Datta,et al.  DNA Repair Pathway Stimulated by the Forkhead Transcription Factor FOXO3a Through the Gadd45 Protein , 2002, Science.

[13]  J. Trent,et al.  α-methylacyl-CoA racemase: A new molecular marker for prostate cancer , 2002 .

[14]  Kimberly Walter,et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. , 2002, The American journal of pathology.

[15]  E. Meese,et al.  The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex. , 2002, Blood.

[16]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  Kenneth M. Yamada,et al.  Fibronectin, integrins, and growth control , 2001, Journal of cellular physiology.

[18]  G. delle Fave,et al.  p27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. , 2001, Human pathology.

[19]  M. Amin,et al.  Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues , 2001, The Prostate.

[20]  M. Rowe,et al.  CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-kappaB. , 2001, Blood.

[21]  J. Cameron,et al.  Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. , 2001, Cancer research.

[22]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Rowe,et al.  CD 99 expression is positively regulated by Sp 1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-k B , 2001 .

[24]  A. Scarpa,et al.  High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. , 2001, Cancer research.

[25]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[26]  J. Weitzman,et al.  JunD protects cells from p53-dependent senescence and apoptosis. , 2000, Molecular cell.

[27]  A. Maitra,et al.  Detection of t(11;22)(q24;q12) Translocation and EWS-FLI-1 Fusion Transcript in a Case of Solid Pseudopapillary Tumor of the Pancreas , 2000, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[28]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[29]  N. Sampas,et al.  Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.

[30]  S. H. Kim,et al.  Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. , 2000, Blood.

[31]  L. Sobin,et al.  Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.

[32]  Y. Wu,et al.  Plasma Insulin-Like Growth Factor-I and Serum IGF-Binding Protein 3 Can Be Associated with the Progression of Breast Cancer, and Predict the Risk of Recurrence and the Probability of Survival in African-American and Hispanic Women , 1999, Oncology.

[33]  G. Klöppel,et al.  Classification of neuroendocrine tumours. , 1999, Italian journal of gastroenterology and hepatology.

[34]  I. Shih.  The role of CD146 (Mel‐CAM) in biology and pathology , 1999, The Journal of pathology.

[35]  R. Glazer,et al.  Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. , 1999, Molecular pharmacology.

[36]  R. Fiocca,et al.  Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  E. Ruoslahti,et al.  Fibronectin and its integrin receptors in cancer. , 1999, Advances in cancer research.

[38]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[39]  I. Shih,et al.  Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  K. Kinzler,et al.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells. , 1995, Cancer research.

[41]  B Calabretta,et al.  Overexpression of DR-nm23, a protein encoded by a member of the nm23 gene family, inhibits granulocyte differentiation and induces apoptosis in 32Dc13 myeloid cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Berger,et al.  A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. , 1995, Blood.

[43]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[44]  J. Johnson,et al.  MUC18, a melanoma-progression associated molecule, and its potential role in tumor vascularization and hematogenous spread. , 1994, Cancer research.

[45]  C. S. Lee,et al.  Malignant potential of aneuploid pancreatic endocrine tumours , 1993, The Journal of pathology.

[46]  H Kovar,et al.  MIC2 is a specific marker for ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration , 1991, Cancer.

[47]  S. Cole,et al.  The E2 antigen, a 32 kd glycoprotein involved in T‐cell adhesion processes, is the MIC2 gene product. , 1989, The EMBO journal.

[48]  P. Goodfellow,et al.  A pseudoautosomal gene in man. , 1986, Science.

[49]  M. Humphries,et al.  A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. , 1986, Science.